Validation of the M. D. Anderson Symptom Inventory Multiple Myeloma Module

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2013 Feb 7

PMID 23384030

Citations 32

Authors

Desiree Jones

Elisabeth G Vichaya

Xin Shelley Wang

Loretta A Williams

Nina D Shah

Sheeba K Thomas

Valen E Johnson

Richard E Champlin

Charles S Cleeland

Tito R Mendoza

Affiliations

Soon will be listed here.

Abstract

Background: The symptom burden associated with multiple myeloma (MM) is often severe. Presently, no instrument comprehensively assesses disease-related and treatment-related symptoms in patients with MM. We sought to validate a module of the M. D. Anderson Symptom Inventory (MDASI) developed specifically for patients with MM (MDASI-MM).

Methods: The MDASI-MM was developed with clinician input, cognitive debriefing, and literature review, and administered to 132 patients undergoing induction chemotherapy or stem cell transplantation. We demonstrated the MDASI-MM's reliability (Cronbach α values); criterion validity (item and subscale correlations between the MDASI-MM and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and the EORTC MM module (QLQ-MY20)), and construct validity (differences between groups by performance status). Ratings from transplant patients were examined to demonstrate the MDASI-MM's sensitivity in detecting the acute worsening of symptoms post-transplantation.

Results: The MDASI-MM demonstrated excellent correlations with subscales of the 2 EORTC instruments, strong ability to distinguish clinically different patient groups, high sensitivity in detecting change in patients' performance status, and high reliability. Cognitive debriefing confirmed that the MDASI-MM encompasses the breadth of symptoms relevant to patients with MM.

Conclusion: The MDASI-MM is a valid, reliable, comprehensive-yet-concise tool that is recommended as a uniform symptom assessment instrument for patients with MM.

Citing Articles

Severity of Symptoms as an Independent Predictor of Poor Outcomes in Patients with Advanced Cancer Presenting to the Emergency Department: Secondary Analysis of a Prospective Randomized Study.

Qdaisat A, Stroh E, Reyes-Gibby C, Wattana M, Viets-Upchurch J, Li Z Cancers (Basel). 2024; 16(23).

PMID: 39682175 PMC: 11640218. DOI: 10.3390/cancers16233988.

Trajectory, interactions, and predictors of higher symptom burden during induction therapy for multiple myeloma.

Kamal M, Shi Q, Shen S, Cleeland C, Wang X J Patient Rep Outcomes. 2024; 8(1):141.

PMID: 39630196 PMC: 11618278. DOI: 10.1186/s41687-024-00817-6.

Effects of tamoxifen on cognitive function in patients with primary breast cancer.

Luijendijk M, Buijs S, Jager A, Koolen S, van der Wall E, Schagen S Br J Cancer. 2024; 132(2):180-187.

PMID: 39592740 PMC: 11747089. DOI: 10.1038/s41416-024-02914-1.

Effects of physical exercise during adjuvant chemotherapy for breast cancer on long-term tested and perceived cognition: results of a pragmatic follow-up study.

Naaktgeboren W, Koevoets E, Stuiver M, van Harten W, Aaronson N, van der Wall E Breast Cancer Res Treat. 2024; 205(1):75-86.

PMID: 38285111 PMC: 11062992. DOI: 10.1007/s10549-023-07220-7.

Guidelines for the Use and Reporting of Patient-Reported Outcomes in Multiple Myeloma Clinical Trials.

Laane E, Salek S, Oliva E, Bennink C, Clavreul S, Richardson P Cancers (Basel). 2023; 15(24).

PMID: 38136310 PMC: 10741926. DOI: 10.3390/cancers15245764.

References

Cleeland C, GONIN R, Baez L, Loehrer P, Pandya K . Pain and treatment of pain in minority patients with cancer. The Eastern Cooperative Oncology Group Minority Outpatient Pain Study. Ann Intern Med. 1998; 127(9):813-6. DOI: 10.7326/0003-4819-127-9-199711010-00006. View

Dubois D, Dhawan R, van de Velde H, Esseltine D, Gupta S, Viala M . Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma. J Clin Oncol. 2006; 24(6):976-82. DOI: 10.1200/JCO.2005.04.0824. View

Leger C, Bredeson C, Kearns B, Bence-Bruckler I, Atkins H, Huebsch L . Autologous blood and marrow transplantation in patients 60 years and older. Biol Blood Marrow Transplant. 2000; 6(2A):204-10. DOI: 10.1016/s1083-8791(00)70044-9. View

Aaronson N, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez N . The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85(5):365-76. DOI: 10.1093/jnci/85.5.365. View

Sherman A, Simonton S, Latif U, Spohn R, Tricot G . Psychosocial adjustment and quality of life among multiple myeloma patients undergoing evaluation for autologous stem cell transplantation. Bone Marrow Transplant. 2004; 33(9):955-62. DOI: 10.1038/sj.bmt.1704465. View

Wang X, Wang Y, Guo H, Mendoza T, Hao X, Cleeland C . Chinese version of the M. D. Anderson Symptom Inventory: validation and application of symptom measurement in cancer patients. Cancer. 2004; 101(8):1890-901. DOI: 10.1002/cncr.20448. View

Rosenthal D, Mendoza T, Chambers M, Asper J, Gning I, Kies M . Measuring head and neck cancer symptom burden: the development and validation of the M. D. Anderson symptom inventory, head and neck module. Head Neck. 2007; 29(10):923-31. DOI: 10.1002/hed.20602. View

Chapko M, Syrjala K, Schilter L, Cummings C, Sullivan K . Chemoradiotherapy toxicity during bone marrow transplantation: time course and variation in pain and nausea. Bone Marrow Transplant. 1989; 4(2):181-6. View

Nejmi M, Wang X, Mendoza T, Gning I, Cleeland C . Validation and application of the Arabic version of the M. D. Anderson symptom inventory in Moroccan patients with cancer. J Pain Symptom Manage. 2010; 40(1):75-86. DOI: 10.1016/j.jpainsymman.2009.12.007. View

10.

Serlin R, Mendoza T, Nakamura Y, Edwards K, Cleeland C . When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain. 1995; 61(2):277-284. DOI: 10.1016/0304-3959(94)00178-H. View

11.

Cocks K, Cohen D, Wisloff F, Sezer O, Lee S, Hippe E . An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer. 2007; 43(11):1670-8. DOI: 10.1016/j.ejca.2007.04.022. View

12.

Cohen J . A power primer. Psychol Bull. 2009; 112(1):155-9. DOI: 10.1037//0033-2909.112.1.155. View

13.

Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E . Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6):649-55. View

14.

Mendoza T, Wang X, Cleeland C, Morrissey M, Johnson B, Wendt J . The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer. 1999; 85(5):1186-96. DOI: 10.1002/(sici)1097-0142(19990301)85:5<1186::aid-cncr24>3.0.co;2-n. View

15.

Armstrong T, Mendoza T, Gning I, Gring I, Coco C, Cohen M . Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT). J Neurooncol. 2006; 80(1):27-35. DOI: 10.1007/s11060-006-9135-z. View

16.

Cleeland C, Mendoza T, Wang X, Chou C, Harle M, Morrissey M . Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer. 2000; 89(7):1634-46. DOI: 10.1002/1097-0142(20001001)89:7<1634::aid-cncr29>3.0.co;2-v. View

17.

Kirkova J, Davis M, Walsh D, Tiernan E, OLeary N, LeGrand S . Cancer symptom assessment instruments: a systematic review. J Clin Oncol. 2006; 24(9):1459-73. DOI: 10.1200/JCO.2005.02.8332. View

18.

Mystakidou K, Cleeland C, Tsilika E, Katsouda E, Primikiri A, Parpa E . Greek M.D. Anderson Symptom Inventory: validation and utility in cancer patients. Oncology. 2004; 67(3-4):203-10. DOI: 10.1159/000081318. View

19.

Wagner L, Robinson Jr D, Weiss M, Katz M, Greipp P, Fonseca R . Content development for the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM): use of qualitative and quantitative methods for scale construction. J Pain Symptom Manage. 2012; 43(6):1094-104. PMC: 3419469. DOI: 10.1016/j.jpainsymman.2011.06.019. View

20.

Mendoza T, Wang X, Lu C, Palos G, Liao Z, Mobley G . Measuring the symptom burden of lung cancer: the validity and utility of the lung cancer module of the M. D. Anderson Symptom Inventory. Oncologist. 2011; 16(2):217-27. PMC: 3228083. DOI: 10.1634/theoncologist.2010-0193. View